GEN - Genetic Engineering and Biotechnology News5d
StockWatch: Will Trump Tariffs Return Biopharma Manufacturing to the U.S.?
With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...
Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects
Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...
Pharmaceutical Technology6d
MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drug
Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...
MPR6d
Nemvaleukin/Pembrolizumab Combo Fails to Meet Endpoint in Ovarian Cancer Trial
Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.
Oncology Nursing News6d
Nemvaleukin Lacks OS Benefit Over Chemo in Platinum-Resistant Ovarian Cancer
Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...